We evaluated a comprehensive set of clinical and biological endpoints, including patient demographics, tumor histology, molecular and genomic profiles, laboratory biomarkers (such as LDH, CRP, and NLR), and patterns of disease progression. Here, CRP is linked to neoplasm.